Milestone Pharmaceuticals Inc

Milestone Pharmaceuticals’ FDA‑approved CARDAMYST nasal spray sparks insider buying and a path to revenue—learn how executive confidence and payer strategy could drive commercial success.

Milestone Pharmaceuticals’ 10b5‑1 insider trades reveal disciplined liquidity management—boosting R&D funding, market access, and partnership potential for its metabolic‑disorder pipeline.